Publications
- Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs2014 | Second Faculty of Medicine, Central Library of Charles University
- Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials2011 | Second Faculty of Medicine
- Type I interferon and cancer2024 | Second Faculty of Medicine
- Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma2023 | First Faculty of Medicine, Second Faculty of Medicine
- Trial watch: chemotherapy-induced immunogenic cell death in oncology2023 | Second Faculty of Medicine
- Interferon signaling restrains renal cell carcinoma heterogeneity2023 | Second Faculty of Medicine
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial2022 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors2022 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines2022 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...